February 15, 2013 / 4:35 PM / 4 years ago

Sanofi says Gaucher pill meets goals in late-stage tests

1 Min Read

PARIS, Feb 15 (Reuters) - Sanofi said on Friday its experimental pill for Gaucher disease met its main targets in two late-stage studies, which the French drugmaker will use to bolster its case for regulatory approval.

If approved, eliglustat tartrate could become the first-oral treatment for Gaucher disease, a rare genetic disorder affecting some 10,000 patients worldwide.

Reporting by Elena Berton; Editing by Christian Plumb

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below